Canada markets open in 2 hours 12 minutes
  • S&P/TSX

    20,220.49
    -163.28 (-0.80%)
     
  • S&P 500

    3,963.94
    -62.18 (-1.54%)
     
  • DOW

    33,849.46
    -497.57 (-1.45%)
     
  • CAD/USD

    0.7431
    +0.0018 (+0.24%)
     
  • CRUDE OIL

    79.13
    +1.89 (+2.45%)
     
  • BTC-CAD

    22,182.03
    +217.98 (+0.99%)
     
  • CMC Crypto 200

    389.64
    +9.35 (+2.46%)
     
  • GOLD FUTURES

    1,770.20
    +14.90 (+0.85%)
     
  • RUSSELL 2000

    1,830.96
    -38.23 (-2.05%)
     
  • 10-Yr Bond

    3.7030
    0.0000 (0.00%)
     
  • NASDAQ futures

    11,672.75
    +56.50 (+0.49%)
     
  • VOLATILITY

    22.15
    +1.65 (+8.05%)
     
  • FTSE

    7,529.45
    +55.43 (+0.74%)
     
  • NIKKEI 225

    28,027.84
    -134.99 (-0.48%)
     
  • CAD/EUR

    0.7159
    -0.0004 (-0.06%)
     

Helix BioPharma Corp. Announces Scientific Collaboration with University Hospital Tuebingen

Toronto, Ontario --News Direct-- Helix BioPharma Corp.

Toronto, Ontario – TheNewswire – August 9, 2022 – Helix BioPharma Corp. (TSX:HBP) (OTC:HBPCF) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, is pleased to announce that it has entered into a two-year scientific collaboration agreement (“Agreement”) with University Hospital Tuebingen (Germany) to assess the therapeutic response of L-DOS47 in several cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.

We aim to explore the potential synergistic effects of L-DOS47 in combination with checkpoint inhibitors on relevant cancer models. To accomplish this overarching aim, Helix established a two-year collaborative partnership with a unique team from the University Hospital Tuebingen to gain further insights into the effects of L-DOS47 on the tumor microenvironment and pH modulation in vivo. In addition, the collaboration also explores the potential for designing novel LDOS47-based radiotracers with application in translational immune-oncology and molecular imaging.

Mr. Artur Gabor, CEO of Helix, commented, “We are excited to collaborate with the University Hospital of Tuebingen and especially the Medical Faculty, which have relevant experience and knowledge in molecular imaging, particularly the method of AcidoCEST, which makes pH changes in the tumor microenvironment visible through a color change. We expect this collaboration to result in new and additional insight into the therapeutic response of L-DOS47 in several not yet explored preclinical cancer models expressing CEACAM6.”

Prof. André F. Martins (Ph.D., Department of Preclinical Imaging and Radiopharmacy) and Manfred Kneilling (MD, Department of Preclinical Imaging and Radiopharmacy & Department of Dermatology) of the University of Tuebingen said, “We are pleased to work with Helix on this exciting project. Our technological advances combined with Helix’ L-DOS47, which has already shown promising preclinical and clinical safety data, will allow us to gain further insights into its unique mechanism of action. L-DOS47 might be in combination with immune check point inhibitor-based immunotherapies and other targeted therapies applicable to promote tumors regression and thus to improve the treatment efficacy and hopefully long-term survival.” Prof. Martins and Kneilling are members of the “Image-Guided and Functionally Instructed Tumor Therapies” (iFIT) Cluster of Excellence at the University of Tuebingen. iFIT is the only oncology-based cluster in Germany, a research consortium aiming to develop innovative and sustainable cancer therapies.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer, based on the proprietary technology platform DOS47. Helix is listed on the TSX under the symbol “HBP.”

About University Hospital Tuebingen

Founded in 1805, the University Hospital Tuebingen is one of the leading centers of German university medicine. With its close ties to the Medical Faculty of the University of Tuebingen, it is one of 35 University Hospitals in Germany contributing to a successful combination of top-level medicine, research, and teaching. Its experts collaborate across disciplines and offer state-of-the-art treatment to more than 400,000 in- and outpatients worldwide each year. Neurosciences, Oncology and Immunology, Infection Biology, Vascular Medicine, and Diabetes are focus areas of research at the Medical Faculty of Tuebingen. https://www.medizin.uni-tuebingen.de/en-de/

About L-DOS47

L-DOS47 is Helix’s first immunoconjugate-based drug candidate in development based on the Company’s novel DOS47 platform technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction.

For more information, please contact:

Helix BioPharma Corp.

Suite 2704, 401 Bay Street Toronto, Ontario, M5H 2Y4

Tel: 905-841-2300

Namrata Malhotra, Corporate Secretary

namrata@grovecorp.ca

Forward-Looking Statements and Risks and Uncertainties

This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s future business, operations, research and development, including the Company’s activities relating to DOS47, and statements regarding expected improvements to the Company’s independence, diversification and corporate governance and the Company’s expectations regarding strengthening its future growth capabilities. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.

Forward-looking statements are statements about the future and are inherently uncertain and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward- looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management’s current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release.

The Company’s actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation; the risk that the Company’s assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company’s research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company’s anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in the Company’s annual management’s discussion and analysis for the year ended July 31, 2021 under the heading “Risks and Uncertainties” and Helix’s Annual Information Form, in particular under the headings “Forward-looking Statements” and “Risk Factors”, and other reports filed under the Company’s profile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix’s management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

View source version on newsdirect.com: https://newsdirect.com/news/helix-biopharma-corp-announces-scientific-collaboration-with-university-hospital-tuebingen-583638607